Trials / Completed
CompletedNCT00931281
Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir
A Blinded, Randomized, Nonfasting, Placebo-Controlled Study in Healthy Adults to Evaluate Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Ascending Doses of ABT-450 With Ritonavir
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of multiple doses of an experimental hepatitis C virus (HCV) protease inhibitor with ritonavir in healthy volunteers.
Detailed description
This is a multiple ascending dose, non-fasting, open label, randomized study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-450 | capsules, QD or BID, 14 days, ascending doses |
| DRUG | ritonavir | capsules, QD or BID, 14 days, ascending doses |
| DRUG | Placebo for ABT-450 | capsule, QD or BID, 14 days |
| DRUG | Placebo for ritonavir | capsule, QD or BID, 14 days |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2009-09-01
- First posted
- 2009-07-02
- Last updated
- 2010-10-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00931281. Inclusion in this directory is not an endorsement.